What’s Next for HIV Vaccines:
From Design to Efficacy Testing
Satellite Session at IAS 2015
The rapidly evolving field of HIV prevention research includes several promising strategies to prevent or treat HIV with a vaccine. The Enterprise and stakeholders organized a 2-hour, interactive session at IAS 2015 on July 19 to explore the latest in HIV vaccine design, development and testing.
The session addressed questions such as:
- What are the most promising, cross-platform approaches in development for preventive and therapeutic vaccines?
- Where are we in efforts to build on the success of the RV144 trial?
- What is the field learning from studies on novel immunogen design, unique vector platforms, mosaic antigen inserts and prime-boost vaccine regimens?
- What is the role of emerging strategies to administer broadly neutralizing antibodies by passive immunization?
- How do innovative efficacy trial designs optimize the evaluation of HIV vaccine candidates?
Speakers and Panelists
- Nina Russell, Bill & Melinda Gates Foundation
- Mary Marovich, National Institute of Allergy and Infectious Diseases
- Nelson Michael, US Military HIV Research Program
- Dan Barouch, Beth Israel Deaconess Medical Center
- Allan deCamp, HIV Vaccine Trials Network
- Frank Tomaka, Janssen Pharmaceuticals
Organized by the Stakeholders of the Enterprise
- Bill & Melinda Gates Foundation
- HIV Vaccine Trials Network
- International AIDS Vaccine Initiative
- Institut National de la Santé et de la Recherche Médicale
- US Military HIV Research Program
- National Institute of Allergy and Infectious Diseases